Clinical
RSSArticles
-
Attacks on Contraception Access Happening in Abortion-Ban States
Faster than most reproductive health providers could have anticipated, some abortion-ban states, politicians, and institutions have attacked contraception access. Some predict a coordinated attack on contraception in 2023 in states that have already toyed with the idea of banning emergency contraception and IUDs.
-
CDC Tries Less Rigid Approach to Opioid Prescribing Guidelines
Agency underscores voluntary nature of its recommendations, highlights new science and collaboration that went into the revisions.
-
Advocates Underscore Importance of Colonoscopies
Follow-up media reports about possibly incomplete research on this subject may have created confusion.
-
Scientists Are Worried About Air Quality and Dementia Risk
Traffic-related air pollution raises red flags for neurological health.
-
Researchers: Telehealth Visits OK for High Blood Pressure Monitoring
Although there was no difference in long-term outcomes, patients treated virtually were happier with their care than those who went to the clinic.
-
A Review of Psilocybin in Treating Depression
This literature review examines the research that has gone into the use of psilocybin specifically to treat depression. An examination of the available evidence demonstrates significant promise in psilocybin’s efficacy to treat depression, although more research is needed to make the results generalizable.
-
Long-Term Neurological Outcomes of Patients Treated with CAR-T Therapy
Chimeric antigen receptor (CAR)-T cell therapy is approved for the treatment of lymphoma, leukemia, and multiple myeloma, but its use is associated with early neurotoxicity in almost half of patients. Despite the incidence of neurotoxicity, long-term follow-up of patients after CAR-T infusion suggests that patients’ neurological examination, neuro-imaging studies, and cognition remain unaffected by this treatment.
-
Treatment of Progressive Multifocal Leukoencephalopathy
Progressive multifocal leukoencephalopathy, a rare opportunistic viral infection that occurs in patients who have chronic immunosuppression, has defied all attempts at treatment. This observational study, which pooled patient data from multiple centers around the world, showed that there is some benefit using checkpoint inhibitors to help reconstitute the immune system of these patients. However, survival, at best, is 50% of those treated.
-
Intravenous Immunoglobulin in Dermatomyositis
Treatment of dermatomyositis with intravenous immunoglobulin (IVIG) resulted in overall better clinical improvement after 16 weeks compared to patients treated with placebo. However, there was a significant number of thromboembolic adverse events in the treatment group. The group of patients treated was a heterogeneous group. However, IVIG now is U.S. Food and Drug Administration-approved for the treatment of dermatomyositis.
-
Is IVIG Treatment Really Better than Natural Recovery in Patients with Guillain-Barré Syndrome?
In this controversial report comparing patients with Guillain-Barré syndrome treated with intravenous immunoglobulin vs. no treatment, the group that appears to have fared the best were patients who had an acute demyelinating syndrome, and not an axonal variant. This was an observational study and not a randomized treatment trial.